Incyte pays Genesis $80M to expand AI-fueled drug discovery pact
Incyte is paying Genesis $80 million upfront to expand use of its partner’s AI platform across a broader range of targets, continuing the biotech’s rapid embrac...
Incyte is paying Genesis $80 million upfront to expand use of its partner’s AI platform across a broader range of targets, continuing the biotech’s rapid embrace of AI in drug discovery and development.